ArticleDiagnostic pathology2025
Clinical significance and expression of ALDH1 in triple-negative breast cancer.
Article in Diagnostic pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unleashing lncRNA THOR: roles in cancer progression and clinical outlook.Molecular genetics and genomics : MGG · 2026Review
- Cancer stem cell markers, chemotherapy response, and survival in triple-negative breast cancer.World journal of clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) is aggressive and has limited therapeutic options due to the absence of targeted therapies, highlighting the urgent need for prognostic biomarkers linked to cancer stemness and chemoresistance. Aldehyde dehydrogenase 1 (ALDH1), a key regulator of stem cell properties, remains incompletely characterized in TNBC clinical cohorts.
methodsALDH1 mRNA expression levels were analyzed using the GEO2R online database, and its prognostic significance was assessed via the Kaplan‒Meier plotter tool. Immunohistochemical (IHC) staining was performed on a tissue microarray comprising 96 TNBC samples and paired adjacent normal tissues from patients treated at Binzhou People's Hospital between 2016 and 2022. The associations between ALDH1 expression and clinicopathological parameters were evaluated using the chi-square test.
resultsBioinformatics analysis revealed significantly higher ALDH1 mRNA expression in TNBC tissues compared to adjacent benign tissues. Kaplan‒Meier survival analysis demonstrated that elevated ALDH1 mRNA expression was associated with poor prognosis in TNBC patients. IHC staining further confirmed elevated ALDH1 protein expression in TNBC tissues compared with normal adjacent tissues. However, there was no significant correlation between ALDH1 expression and conventional clinicopathological parameters, including age, menopausal status, tumor size, TNM stage, histological grade, histological subtype, axillary lymph node metastasis and the Ki-67 index (p > 0.05). High ALDH1 expression was significantly associated with poorer overall survival ( χ
conclusionOur data demonstrate that ALDH1 expression is not significantly associated with conventional clinicopathological parameters (such as age, TNM stage, or histological grade). Instead, it is associated with poorer survival on univariate analysis in TNBC patients. Its lack of association with clinicopathological factors suggests its potential utility as a supplementary prognostic indicator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.